Start-Up Quarterly Statistics, Q3 2010

In the third quarter of 2010, biopharma, medical device, and in vitro diagnostics start-ups brought in a total of $780 million, a 29% jump from the previous quarter and a 50% increase from the third quarter of 2009. ( See Exhibit 1.) Biopharma companies did well in Q3, bringing in $446 million, or 30% more than the previous quarter. Not so for in vitro diagnostics start-ups, which raised just $99 million, 39% less than they did in Q2. Device companies were the most successful at generating more funds compared with Q2 – with a 130% hike. (This spike was mostly due to Devicor Medical Products Inc.'s equity financing, which accounted for 66% of Q3's device total.)

Devicor was the clear fundraising champion in Q3. In what appears to be its first outside financing round (GTCR Golder Rauner LLC committed up to $250 million when it formed Devicor in 2008), the medical device holding company brought in $151.5 million from seven investors